A novel paclitaxel-loaded poly(d,l-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment

Abstract

Drug resistance has become a main obstacle for the effective treatment of lung cancer. To address this problem, a novel biocompatible nanoscale package, poly(d,l-lactide-co-glycolide)-Tween 80, was designed and synthesized to overcome paclitaxel (PTX) resistance in a PTX-resistant human lung cancer cell line. The poly(d,l-lactide-co-glycolide) (PLGA)-Tween 80 nanoparticles (NPs) could efficiently load PTX and release the drug gradually. There was an increased level of uptake of PLGA-Tween 80 in PTX-resistant lung cancer cell line A549/T, which achieved a significantly higher level of cytotoxicity than both PLGA NP formulation and Taxol^®. The in vivo antitumor efficacy also showed that PLGA-Tween 80 NP was more effective than Taxol^®, indicating that PLGA-Tween 80 copolymer was a promising carrier for PTX in resistant lung cancer.

Keywords:

• poly(d,l-lactide-co-glycolide)
• Tween 80
• nanoparticle
• drug resistance
• lung cancer

Acknowledgments

This work was supported by NSFC no 81301929 and National Key Scientific Instrument Special Program of China no 2013YQ030923 and Hubei Province Health and Family Planning Scientific Research Project no WJ2015Q009.

Disclosure

The authors report no conflicts of interest in this work.